JP2016501858A - 転移性癌を処置するためのｃｄ４４ｖ６由来ペプチド - Google Patents

転移性癌を処置するためのｃｄ４４ｖ６由来ペプチド Download PDF

Info

Publication number
JP2016501858A
JP2016501858A JP2015543432A JP2015543432A JP2016501858A JP 2016501858 A JP2016501858 A JP 2016501858A JP 2015543432 A JP2015543432 A JP 2015543432A JP 2015543432 A JP2015543432 A JP 2015543432A JP 2016501858 A JP2016501858 A JP 2016501858A
Authority
JP
Japan
Prior art keywords
group
peptide
cancer
amino acids
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015543432A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501858A5 (enExample
Inventor
オリアン−ルソー，ベロニーク
マッケ，アレクサンドラ
ポンタ，ヘルムト
Original Assignee
アムキュア ゲーエムベーハー
アムキュア ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムキュア ゲーエムベーハー, アムキュア ゲーエムベーハー filed Critical アムキュア ゲーエムベーハー
Publication of JP2016501858A publication Critical patent/JP2016501858A/ja
Publication of JP2016501858A5 publication Critical patent/JP2016501858A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015543432A 2012-11-21 2013-11-21 転移性癌を処置するためのｃｄ４４ｖ６由来ペプチド Pending JP2016501858A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1220889.8 2012-11-21
GBGB1220889.8A GB201220889D0 (en) 2012-11-21 2012-11-21 CD44v6-derived peptides for treating metastasizing cancers
PCT/EP2013/074404 WO2014079943A1 (en) 2012-11-21 2013-11-21 Cd44v6-derived peptides for treating metastasizing cancers

Publications (2)

Publication Number Publication Date
JP2016501858A true JP2016501858A (ja) 2016-01-21
JP2016501858A5 JP2016501858A5 (enExample) 2016-12-22

Family

ID=47521460

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015543432A Pending JP2016501858A (ja) 2012-11-21 2013-11-21 転移性癌を処置するためのｃｄ４４ｖ６由来ペプチド

Country Status (13)

Country Link
US (1) US9593146B2 (enExample)
EP (1) EP2922563B1 (enExample)
JP (1) JP2016501858A (enExample)
AU (1) AU2013349703B2 (enExample)
CA (1) CA2892147A1 (enExample)
DK (1) DK2922563T3 (enExample)
ES (1) ES2765037T3 (enExample)
GB (1) GB201220889D0 (enExample)
HU (1) HUE047126T2 (enExample)
IL (1) IL238606B (enExample)
LT (1) LT2922563T (enExample)
SI (1) SI2922563T1 (enExample)
WO (1) WO2014079943A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020536104A (ja) * 2017-10-05 2020-12-10 スイヘネリス ファルマコスメティクス, エセ.エレ.Suigeneris Farmacosmetics, S.L. 抗がんペプチド及びその使用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201421647D0 (en) 2014-12-05 2015-01-21 Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases
KR102194025B1 (ko) 2017-12-15 2020-12-22 경북대학교 산학협력단 CD44v6에 결합하는 펩타이드 및 이의 용도
JP7510874B2 (ja) 2017-12-22 2024-07-04 ヒプラ シエンティフィック エセ．エレ．ウ． マイコプラズマ及びブタサーコウイルスに対する皮内混合ワクチン
EP4464714A1 (en) 2023-05-19 2024-11-20 Karlsruher Institut für Technologie Screening method for cell-repelling peptides

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016557A1 (de) * 1995-10-31 1997-05-09 Boehringer Ingelheim International Gmbh TUMORTHERAPIE DURCH ADOPTIVEN TRANSFER CD44v-SPEZIFISCHER ZYTOTOXISCHER T-LYMPHOZYTEN
EP1417974A1 (en) * 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
JP2004529963A (ja) * 2001-05-18 2004-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 細胞傷害性ｃｄ４４抗体免疫コンジュゲート
WO2005065709A2 (de) * 2003-12-24 2005-07-21 Boehringer Ingelheim International Gmbh Gefriergetrocknete formulierung von antikörperkonjugaten
EP1647556A1 (en) * 2004-10-14 2006-04-19 TopoTarget Germany AG Peptidic compounds and derivatives thereof for the treatment of human diseases through inhibition of signaling via growth factors
EP2218457A1 (en) * 2009-02-16 2010-08-18 Karlsruher Institut für Technologie CD44v6 peptides as inhibitors of bacterial infections
EP2266593A1 (en) * 2009-06-24 2010-12-29 Karlsruher Institut für Technologie Use of CD44v6 in the treatment of ophthalmic diseases
WO2011022335A1 (en) * 2009-08-21 2011-02-24 Mount Sinai School Of Medicine Of New York University Methods of using cd44 fusion proteins to treat cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696229A (en) 1995-03-16 1997-12-09 The University Of Virginia Patent Foundation Polypeptide with laminin cell adhesion and morphogenesis activity
JP2003089700A (ja) 2001-09-18 2003-03-28 Life Science Management:Kk ペプチド

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016557A1 (de) * 1995-10-31 1997-05-09 Boehringer Ingelheim International Gmbh TUMORTHERAPIE DURCH ADOPTIVEN TRANSFER CD44v-SPEZIFISCHER ZYTOTOXISCHER T-LYMPHOZYTEN
JP2004529963A (ja) * 2001-05-18 2004-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 細胞傷害性ｃｄ４４抗体免疫コンジュゲート
EP1417974A1 (en) * 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
WO2005065709A2 (de) * 2003-12-24 2005-07-21 Boehringer Ingelheim International Gmbh Gefriergetrocknete formulierung von antikörperkonjugaten
EP1647556A1 (en) * 2004-10-14 2006-04-19 TopoTarget Germany AG Peptidic compounds and derivatives thereof for the treatment of human diseases through inhibition of signaling via growth factors
EP2218457A1 (en) * 2009-02-16 2010-08-18 Karlsruher Institut für Technologie CD44v6 peptides as inhibitors of bacterial infections
EP2266593A1 (en) * 2009-06-24 2010-12-29 Karlsruher Institut für Technologie Use of CD44v6 in the treatment of ophthalmic diseases
WO2011022335A1 (en) * 2009-08-21 2011-02-24 Mount Sinai School Of Medicine Of New York University Methods of using cd44 fusion proteins to treat cancer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
A MATZKE, ET AL., CANCER RES, 2005, 65(14), PP6105-6110, JPN6017034284, ISSN: 0003827486 *
AJCC CANCER STAGING MANUAL SEVENTH EDITION, AMERICAN JOINT COMMITTEE ON CANCER, 2010, PP3-15, JPN7018002198, ISSN: 0003827489 *
M HOFMANN, ET AL., CANCER RESEARCH, 1991, 51, PP5292-5297, JPN6017034292, ISSN: 0003637331 *
M TREMMEL, ET AL., BLOOD, 2009, 114(25), PP5236-5244, JPN6017034287, ISSN: 0003827487 *
MARGOT ZOELLER, NATURE REVIEWS CANCER, vol. V11 N4, JPN5016002244, 10 March 2011 (2011-03-10), pages 254 - 267, ISSN: 0003637332 *
VERONIQUE ORIAN-ROUSSEAU, EUROPEAN J CANCER, 2010, 46, PP1271-1277, JPN6017034289, ISSN: 0003827488 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020536104A (ja) * 2017-10-05 2020-12-10 スイヘネリス ファルマコスメティクス, エセ.エレ.Suigeneris Farmacosmetics, S.L. 抗がんペプチド及びその使用
JP7302887B2 (ja) 2017-10-05 2023-07-04 スイヘネリス ファルマコスメティクス，エセ．エレ． 抗がんペプチド及びその使用

Also Published As

Publication number Publication date
ES2765037T3 (es) 2020-06-05
IL238606A0 (en) 2015-06-30
CA2892147A1 (en) 2014-05-30
US20150183826A1 (en) 2015-07-02
AU2013349703B2 (en) 2016-12-22
DK2922563T3 (da) 2020-01-20
EP2922563B1 (en) 2019-10-30
HUE047126T2 (hu) 2020-04-28
WO2014079943A1 (en) 2014-05-30
EP2922563A1 (en) 2015-09-30
SI2922563T1 (sl) 2020-04-30
LT2922563T (lt) 2020-03-25
US9593146B2 (en) 2017-03-14
IL238606B (en) 2019-07-31
GB201220889D0 (en) 2013-01-02
AU2013349703A1 (en) 2015-07-09

Similar Documents

Publication Publication Date Title
US9593146B2 (en) CD44v6-derived peptides for treating metastasizing cancer
US12121596B2 (en) Near infrared fluorescent dyes, formulations and related methods
CN105431162A (zh) 用于治疗血管生成依赖性和淋巴管生成依赖性疾病的生物模拟肽和生物可降解的递送平台
WO2017143115A2 (en) Enhancing the therapeutic activity of an immune checkpoint inhibitor
EP2266593A1 (en) Use of CD44v6 in the treatment of ophthalmic diseases
WO2014079914A1 (en) Cd44v6-derived pegylated peptides
US9586993B2 (en) CD44v6-derived peptides for treating pancreatic cancer
EP3076988B1 (en) Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer
TWI630910B (zh) 供靶向、造影及治療前列腺癌之胜肽共軛奈米粒子
US20170305995A1 (en) CD44V6-Derived Peptides for Treating Metastasizing Cancer
US9586994B2 (en) CD44V6-derived peptides for treating breast cancer
HK40052573A (en) Detection of colonic neoplasia in vivo using near-infrared peptide targeted against overexpressed cmet
CN113454099A (zh) 使用靶向过表达cMET的近红外肽在体内检测结肠瘤形成
US20250001016A1 (en) Near Infrared Fluorescent Dyes, Formulations and Related Methods
HK1229242B (en) Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer
HK1229242A1 (en) Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer
Cupka Development of an αᵥβ₆-Binding Peptide for In Vivo Applications: Modulation of Serum Stability and Biodistribution

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20150520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170912

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180703